Introduction {#Sec1}
============

Most mechanically ventilated critically ill patients require sedation and analgesia. Deep sedation is associated with adverse outcomes including higher mortality \[[@CR1], [@CR2]\], and strategies that systematically avoid over-sedation improve patient outcomes in both randomised trials \[[@CR3]--[@CR6]\] and quality improvement studies \[[@CR7]--[@CR9]\]. Conversely, light sedation and agitation can compromise patient safety and increase staff workload and stress \[[@CR10]--[@CR12]\].

Recent guidelines recommend the systematic evaluation of pain, agitation, and delirium in intensive care units (ICUs) and implementation of evidence-based strategies to improve patient experience and outcomes \[[@CR13], [@CR14]\]. Although there are valid and reliable clinical tools for diagnosing and rating pain, sedation and delirium \[[@CR15]\], the implementation of practices that identify and systematically avoid unnecessary deep sedation is challenging. There are several technologies for monitoring sedation status based on electroencephalogram (EEG) analysis, but these were developed primarily for monitoring the depth of anaesthesia and their validity for use in ICU patients is uncertain \[[@CR16]\]. Although these algorithms correlate with clinical sedation scores, their discriminant ability is limited, in part because of interference from facial frontal electromyelogram (fEMG) signals during arousals and in lighter sedation states \[[@CR17], [@CR18]\]. There have been few randomised trials of these technologies, and the available data do not support clinical effectiveness \[[@CR13], [@CR19]\].

We recently described a novel technology for continuous monitoring of patient status in ICU patients, the Responsiveness Index (RI), based on fEMG activity \[[@CR20]--[@CR22]\]. The algorithm uses fEMG data acquired via adhesive surface forehead electrodes, and utilises the previous 60 minutes of fEMG activity to assess the frequency and intensity of arousals during ongoing treatments. RI has been shown to perform better than an EEG-based algorithm \[[@CR21]\], and to have face and criterion validity compared with clinical sedation states \[[@CR20]\].

Our aim in this proof-of-concept trial was to assess the effectiveness, safety, and acceptability of continuous RI monitoring during early ICU care as a nurse decision-support tool. We hypothesised that continuous RI monitoring as an adjunct to clinical sedation scoring would decrease the period of low patient responsiveness without excess adverse events, compared to a control group treated according to current best practice. We aimed to use both quantitative and qualitative approaches to provide early effectiveness, safety and acceptability data.

Methods {#Sec2}
=======

We undertook a prospective single-centre randomised parallel-group controlled proof-of-concept trial, including qualitative analysis of interviews with nursing staff utilising the RI monitor.

Patients and setting {#Sec3}
--------------------

The study took place in an 18-bed Scottish general adult ICU admitting approximately 650 ventilated medical, surgical, and trauma patients annually (excluding routine cardiac surgery and neuro-intensive care). Patients were screened by clinical nursing staff at the time of ICU admission. Inclusion criteria were that patients were mechanically ventilated via an endotracheal tube, and receiving intravenous sedation with a hypnotic agent by continuous infusion. Exclusion criteria were patients who had a primary intracerebral disorder (including post-cardiac arrest, intracranial haemorrhage, or head injury causing a reduced level of consciousness prior to intubation); were already conscious at the time of enrolment defined as Richmond agitation-sedation scale (RASS) score \[[@CR23]\] ≥ −1; were aged \<16 years; were not expected to survive the next 24 hours; were receiving long-term ventilation prior to ICU admission; had a long-term tracheostomy prior to ICU admission; had been transferred sedated and mechanically ventilated from another ICU (unless recruitment was possible within 24 hours of the first ICU admission); were receiving continuous neuromuscular blocking agent (NMBA) at the time of screening; had previously been enroled in the trial; had status epilepticus; had confirmed meningitis or encephalitis, or had a known chronic neurological disease interfering with normal neuromuscular function, e.g., motor neurone disease, Guillain-Barre syndrome or inherited neuromyopathy.

Consent and randomization {#Sec4}
-------------------------

Consent was deferred to enable the establishment of responsiveness monitoring close to the time of ICU admission. Relatives or next of kin were approached at the earliest opportunity following admission for consent to remain in the study; patients were approached when they had capacity. Patients in whom consent was not subsequently obtained from a relative, or patients who were withdrawn from the trial were excluded from the analysis (according to Scottish legal requirements). Patients were randomised by nursing staff to one of the two groups by opening sequentially numbered opaque sealed envelopes. The randomisation order was generated using a computer randomisation sequence. No stratification or minimisation was used. The allocation within each envelope directed the clinical nurse to select an RI monitor pre-specified to the control or intervention group (see below). The study was approved by the Scottish A Research Ethics committee (09/MRE00/17).

Study conduct {#Sec5}
-------------

All participating nursing staff received pre-trial training in the use of the Responsiveness monitor, and the concept that low RI values are expected for deeply sedated patients, for some patients in a coma unrelated to sedation, and during natural sleep \[[@CR20]\]. Nurses were also instructed not to use monitor data when patients received NMBAs.

Control group (group 1) {#Sec6}
-----------------------

All patients were attached to the Responsiveness monitor, and data were acquired using a laptop computer. For these patients a monitoring device was used, which did not display any RI data throughout the study. RI data could only be accessed by code by the research team (to check quality etc.), which was not available to clinical staff. The monitor presented an automated prompt every hour during the study to assess the RASS score and enter it into the study case record form (CRF). The prompt flashed on the monitor until a score was entered, and the exact time of entry logged. The local sedation protocol encouraged staff to target a RASS score of \>−3 and to undertake a sedation hold on a daily basis unless clinically contraindicated.

Intervention group (group 2) {#Sec7}
----------------------------

As for group 1, all patients in the intervention group were attached to the Responsiveness monitor, and data collected using a laptop computer. For these patients RI data were presented as a continuous trend, with a numeric value (0--100), and a colour code (red, amber, green) according to our previous published work, which suggested a value with a red colour had sensitivity to detect patients who may be excessively sedated \[[@CR20]\]. An example of a monitor during use is shown in Fig. [1](#Fig1){ref-type="fig"}. Prompts accompanied the colour of RI presented on the screen, to encourage sedation reduction for patients with a red or amber RI value (RI \<40). Nurses were asked to alter sedation using clinical judgement to transition patients out of the red RI range and adjust sedation to achieve values in the amber/green range. In addition, automated prompts occurred every hour for RASS scores as for group 1.Fig. 1Responsiveness Index (RI) sedation monitor used in the trial. For intervention patients, the screen presented a running trend over several hours, with the most recent value presented on an arbitrary scale of 0--100, with a colour code of *RED* (\<20), *AMBER* (20 to 40); and *GREEN* (\>40). In addition to the colour trend, the following prompts were automatically presented according to RI value: *RED* high risk of over-sedation. Ensure adequate analgesia if responsive to stimuli, e.g., suctioning/physiotherapy. Reduce sedation dose if no eye-opening to physical stimuli. *AMBER*: moderate risk of over-sedation. Ensure adequate analgesia. Reduce sedation if no eye-opening to physical stimuli. *GREEN*: low risk of over-sedation. Ensure adequate analgesia. Continue current sedation unless patient agitated

Management during intervention period {#Sec8}
-------------------------------------

The choice of sedative and analgesic drugs, and the initial dosage, was at the discretion of the clinical team. The standard sedative drug was propofol, and the opiate alfentanil at the time of the study. Clinicians could use alternative agents, principally midazolam and morphine, according to clinical discretion. All decisions about other aspects of usual care were made by the clinical team, including the timing of extubation. The only trial-specific interventions were related to changes in the dose of sedatives made by bedside nursing staff in the two study groups. The research team, who were the only individuals with access to the RI data for the control group, was not involved in clinical management.

Study endpoints {#Sec9}
---------------

Responsiveness monitoring was continued until one of the following endpoints occurred:48 hours had elapsed from ICU admissionThe patient was extubatedThe patient died or a decision was made to withdraw treatment

The maximum duration of RI monitoring was 48 hours. This duration was chosen pragmatically for the proof-of-concept study, and to enable comparison for a fixed period of care during which excessive sedation is known to be associated with adverse outcomes \[[@CR1]\].

Discontinuing RI monitoring {#Sec10}
---------------------------

RI monitoring could be discontinued for procedures or other reasons according to clinical judgement. In these cases, monitoring was reattached as soon as feasible if within the 48 hour intervention period.

Data collection {#Sec11}
---------------

Baseline data were age, gender, admission diagnosis, time from hospital to ICU admission, acute physiology and chronic health evaluation (APACHE) II score, Charlson comorbidity index, sequential organ failure assessment (SOFA) score (excluding neurological score) for the first 24 hours (range 0--20), RASS score at the start of monitoring, and intravenous sedation and analgesic drug use in ICU prior to RI monitoring. Hourly data collection during the intervention period was RASS score, and intravenous sedative and analgesic dose. The use of formal sedation holds was recorded on a daily basis. The following pre-defined sedation-related adverse events were recorded: unplanned extubation, unplanned removal of vascular catheter, unplanned removal of nasogastric/enteral tube, episode of myocardial ischaemia, myocardial infarction and agitation requiring pharmacologic treatment.

Outcomes {#Sec12}
--------

Our feasibility outcomes were to test the protocol and determine likely recruitment rates for a large trial. To explore potential clinical effectiveness, acceptability, and safety we measured the following additional outcomes:Proportion of time spent with low responsiveness (red colour code; RI \<20) during the first 48 hours in ICU (or from when first sedated and ventilated)Proportion of time spent with RASS score −4/−5 during first 48 hours (or from when first sedated and ventilated)Sedation-related adverse event rates (comparison of control and intervention groups during intervention period)Duration of mechanical ventilationICU, hospital mortalityTotal sedative drug dose during first 48 hours in the ICU (or from when first sedated and ventilated)Total opioid drug dose during first 48 hours in the ICU (or from when first sedated and ventilated)

We described patient status at 48 hours and 7 days post-randomisation. The full trial protocol is available in the additional material (see Additional file [1](#MOESM1){ref-type="media"}), and is registered at ClinicalTrials.gov: NCT01361230.

Sample size {#Sec13}
-----------

This was a proof-of-concept study so no formal sample size estimation was undertaken. We aimed to randomise 60--70 patients to assess feasibility and provide preliminary efficacy and safety data. Based on ICU admission rates (650 mechanically ventilated cases per year), and an estimated 20--30 % enrolment rate for eligible patients, we planned to recruit for a fixed period of 8 months.

Analysis {#Sec14}
--------

The intervention period was defined as the start of monitoring to 48 hours post ICU admission. Baseline RI was defined as the first valid RI value recorded. For RI analyses patients in whom monitoring was removed because the patient was extubated were assumed to have an RI value \>20 during the post-extubation period. Periods during which NMBAs were used, plus the 30 minutes after discontinuation, were censored from the analysis period. No deaths occurred during the 48-hour intervention period, so competing risk of death was not relevant.

RASS data were pre-processed to impute missing data using several rules: first, if RASS scoring was not performed during a particular hour, the subsequent hourly RASS value was utilized in the analysis; if the subsequent hour had no RASS value, the previous hourly value was used; if neither value was available then that hour was considered to have no RASS data point. For comparisons of total intravenous sedative and analgesic dose during the intervention periods propofol and alfentanil equivalents were calculated for patients who received midazolam and/or morphine as an alternative or addition to propofol/alfentanil. We used a conversion factor of 1 mg midazolam = 10 mg propofol, and 1 mg morphine = 100 μg alfentanil.

Prior to the trial we had no data to inform the distribution of RI values at enrolment. As the intervention aimed to promote transition from an RI value of \<20 (red colour code) to higher RI values (amber/green colour code) we undertook a post hoc subgroup analysis for patients with baseline RI \<20. We justified this analysis because for this group the protocol directed nursing staff to decrease sedation at enrolment, whereas for patients with RI values \>20 the protocol did not direct nurses to alter sedation based on the intervention.

As this was a proof-of-concept study, we restricted analysis to patients treated per protocol with the monitor. We used the Wilcoxon rank-sum test to compare continuous non-parametric data, and Fisher's exact test for categorical data. The log-rank test was used to compare time to first RI value \>20, first RASS score \>−4, and time to extubation. A *P* value \<0.05 was considered statistically significant, but given the exploratory nature of the study we examined trends in addition to statistically significant differences.

Qualitative study {#Sec15}
-----------------

Sixteen nurses with at least 12 hours experience using the monitor in the intervention arm were interviewed to explore their views of sedation management and the potential value of the RI technology. A phenomenological theoretical perspective was taken during analysis. The design of the qualitative study, underpinning theoretical perspective, and qualitative methods used are described in full in the additional material (see Additional file [2](#MOESM2){ref-type="media"}).

Results {#Sec16}
=======

Ninety patients were randomised. No consent was obtained post-randomisation in 12 patients (data could not be utilised according to local ethics approval) (4 in the intervention group and 8 in the control group), a protocol deviation occurred in 4 patients (the randomisation procedure was incorrectly followed by clinical nursing staff in 2 patients, and monitoring was not started by clinical staff during sedation in 2 patients despite randomisation to the intervention group). We included 74 patients in the analysis (36 in the intervention group and 38 in the control group). Patient characteristics and baseline data are shown in Table [1](#Tab1){ref-type="table"}. The patient groups were similar at baseline with respect to all measured variables. Monitoring was started within 8 hours of intubation for \>75 % of participants.Table 1Baseline characteristics and patient status at randomisationBaseline variablesIntervention (n = 36)Control (n = 38)Age, years, median6059(1st, 3rd quartile; min--max)(44, 69; 25--85)(43, 72; 27--80)Sex, male/female21/1526/12Primary diagnosis, number of patients Cardiovascular85 Respiratory39 Gastrointestinal1415 Renal01 Trauma31 Other87APACHE II score, median2023(1st, 3rd quartile; min--max)(11, 24; 0--31)(17, 26; 0--38)Charlson comorbidity index, median11(1st, 3rd quartile; min--max)(0, 2; 0--5)(0, 2; 0--7)SOFA score for first 24 hours, median78(1st, 3rd quartile; min--max)(5, 11; 2--16)(5, 9; 1--16)Time, hours from intubation to start of monitoring, median4.04.9(1st, 3rd quartile; min--max)(2.1, 6.2; 1.0--12.0)(3.5, 7.7; 0.7-- 1.8)RI at start of intervention period, median1618(1st, 3rd quartile; min--max)(0, 55; 0--100)(0, 42; 0--100) Red, n (%)19 (54.3 %)20 (54.1 %) Amber, n (%)5 (14.3 %)8 (21.6 %) Green, n (%)11 (31.4 %)9 (24.3 %) No value, n (%)^a^1 (2.8 %)1 (2.6 %)RASS score at start of intervention period, median−3−4(1st, 3rd quartile; min to max)(−4, −2; −5 to +0)(−4, −3; −5 to +2)Total alfentanil dose, mg, prior to monitoring, median1.753.00(1st, 3rd quartile; min--max)(0.75, 5.25; 0.00--14.00)(1.00, 7.50; 0.00--17.50)^a^One patient in each group had a long delay in commencing Responsiveness Index (*RI*) monitoring by clinical staff after randomisation. These two patients were not given a baseline RI value, and were excluded from the subgroup analysis of patients with RI \<20 at baseline, as the value was uncertain at the start of the study. *APACHE* acute physiology and chronic health evaluation, *SOFA* sequential organ failure assessment, *RASS* Richmond agitation-sedation scale

During the RI monitoring period, NMBAs were administered to 10 patients (6 in the intervention group and 4 in the control group). These were mostly single bolus doses (n = 7); other durations were 30 minutes (n = 2) and 150 minutes (n = 1). The median percentage of time without monitoring was 2 % (1st, 3rd quartile: 0, 7 %) for the intervention and 3 % (0, 8 %) for the control group.

All intervention group patients and 36/38 control patients received propofol during the intervention period; 33/36 intervention group patients and 37/38 control patients received alfentanil. In the intervention group, 4/36 patients received midazolam as did 4/38 control group patients, and 8/36 patients in the intervention group and 7/38 control group patients received morphine during the intervention period. These were converted to propofol and alfentanil equivalents as described above.

A comparison of outcomes between the groups is shown in Table [2](#Tab2){ref-type="table"}. A high perentage of patients (\>80 %) in both groups underwent a sedation hold during the intervention period, and 34/74 patients (46 %) were extubated. Among the entire cohort the intervention group patients tended to have fewer hours with RI \<20, but this was not statistically significant (median 16 % (quartile 1--3, 8--30 %) versus 33 % (10--54 %); *P* = 0.08). Mechanical ventilation status over the 48-hour intervention period is shown in Fig. [2](#Fig2){ref-type="fig"}. There were no statistically significant differences between the groups overall, and no difference in sedation-related adverse events. In the post hoc analysis, 53 % of patients had a baseline RI of \<20 (19 in the intervention group and 20 in the control group). Among these patients those in the intervention group spent less time with RI \<20 (16 % (11--45) in the intervention versus 51 % (33--72) in the control group; *P* = 0.02), and also tended to receive lower cumulative doses of propofol (P = 0.14) and alfentanil (*P* = 0.01) (Table [3](#Tab3){ref-type="table"}). Changes in ventilation and RI status for all patients over the 48 hour-intervention period are illustrated in Fig. [3a](#Fig3){ref-type="fig"}, and for the sub-group with RI \<20 at baseline in Fig. [3b](#Fig3){ref-type="fig"}. These indicated a pattern of quicker extubation and higher RI values over time for the intervention group, especially when the baseline RI was \<20.Table 2Comparison outcomes during the intervention period and at 7 days post-randomisation for the entire study cohortOutcomeIntervention (n = 36)Control (n = 38)*P* valueOutcomes during 48-hour intervention periodProportion of hours during the intervention period with RI value \<20, median16330.08(1st, 3rd quartile; min-- max)(8, 30; 1--87)(10, 54; 0--86)Time, hours from start of monitoring to first RI value \>20, median0.10.30.43(1st, 3rd quartile; min-- max)(0.0, 2.2, 0.0--7.8)(0.0, 3.1, 0.0--48)Proportion of RASS scores of −4 or −5 during the intervention period, median12170.70(1st, 3rd quartile; min-- max)(0, 35; 0--94)(3, 36; 0--100)Time, hours from start of monitoring to first RASS score \>−4, median230.68(1st, 3rd quartile; min-- max)(0, 8, 0--43)(0, 8, 0--48)Total propofol dose, mg, during the intervention period, median1,3651,7300.64(1st, 3rd quartile; min-- max)(380, 2,790; 50--8,710) 1730(620, 3,260; 0--8,630)Total alfentanil dose, mg, during the intervention period, median23.425.20.68(1st, 3rd quartile; min-- max)(9.0, 36.4; 0.0--51.5)(8.6, 36.0; 0.3--87.0)Number (%) of patients undergoing sedation hold during the intervention period30/36 (83)33/38 (87)0.751Number (%) of patients extubated during the intervention period17/36 (47.2 %)17/38 (44.7 %)1.00Proportion of hours in intervention period during which patient extubated, median400.49(1st, 3rd quartile; min-- max)(0--62; 0--92)(0, 44; 0--97)Number (%) of patients with any predefined adverse events during intervention period7/36 (19.4 %)5/38 (13.1 %)0.54Unplanned extubation, number01Unplanned removal of vascular catheter, number00Unplanned removal of nasogastric or other enteral tube, number10Unplanned removal of other drain or device, numberEpisode of myocardial ischaemia, number00Myocardial infarction, number00Episode of agitation requiring bolus treatment with haloperidol or sedative drug (rescue medication), number0064Outcomes at 7 days post-randomisationTime from start of monitoring to first extubation, hours, median42.454.80.52(1st, 3rd quartile; min-- max)(14.7, 168.0; 2.0--168.0)(22.8, 168.0; 1.78--168.0)Deaths, number (%)1/36 (2.8 %)3/38 (7.9 %)0.62Discharged from ICU, number (%)20/36 (55.6 %)18/38 (47.4 %)0.50Still in ICU, number (%)15/36 (41.7 %)15/38 (41.7)1.00Transferred to another ICU, number (%)0/36 (0 %)2/38 (2 %)0.49The intervention period was defined as being from the start of monitoring to 48 hours post ICU admission. *RI* Responsiveness Index, *RASS* Richmond agitation-sedation scaleFig. 2Kaplan-Meier curve illustrating the numbers of patients in each trial group (36 in the intervention and 38 in the control group) requiring mechanical ventilation over the 48-hour intervention period. Log-rank test: *P* = 0.33Table 3Comparison of outcomes for patients analysed in the post hoc exploratory analysis with baseline Responsiveness Index (RI) \<20OutcomeIntervention (n = 19)Control (n = 20)*P* valueProportion of hours during the intervention period with RI value \<20, median16510.02(1st, 3rd quartile; min--max)(11, 45; 2--87)(33, 72; 5--86)RASS score at baseline, median−4−40.76(1st, 3rd quartile; min-max)(−4, −3; −5 to −2)(−4, −3; −5 to 0)Proportion of hours with RASS score −4 or −5 during intervention period, median47350.63(1st, 3rd quartile; min-max)(15, 65; 0--94)(10, 72; 0--100)Total propofol dose (mg) during intervention period, median1,0902,3800.14(1st, 3rd quartile; min-max)(375, 2,965; 100--7,290)(1,510, 3,730; 60--8,630)Total alfentanil dose (mg) during intervention period, median21.232.30.01(1st, 3rd quartile; min-max)(8.5, 27.9; 0.0--49.0)(23.3, 49.8; 1.0--87.0)*RASS* Richmond agitation-sedation scaleFig. 3Description of the numbers of patients remaining intubated over the 48-hour intervention period, together with the numbers of patients with Responsiveness Index (*RI*) values in the *Red*, *Amber*, and *Green* categories at each time point. **a** Summary of data for for all patients in each group. **b** Data restricted to patients in whom the baseline RI value was \<20

Qualitative study {#Sec17}
-----------------

Nursing staff valued the objective visible representation of sedation state, the simple colour representation of trends, and the continuous prompt to manage sedation in contrast to existing intermittent assessments or interventions. The trending was seen as a useful alert and warning, for example, during sedation reduction/interruption. The objective data were also valued in justifying decision-making with medical staff, especially in relation to wakeful or agitated patients. Nurses valued the use of the monitor as an adjunct to decision-making rather being asked to target specific RI values. A full description of the qualitative data analysis and conclusions is provided in the additional material (see Additional file [2](#MOESM2){ref-type="media"}).

Discussion {#Sec18}
==========

We report the first use of RI monitoring to support nurse decision-making in relation to early ICU sedation. Our data suggest that low RI values can safely be used as a prompt to decrease sedative drug use without increasing adverse events. The trend towards lower RI values during the intervention period with RI monitoring, which was statistically significant for the post hoc subgroup analysis of patients with baseline RI \<20, suggest RI monitoring has potential utility for minimising unnecessary early deep sedation.

The RI index utilises fEMG data from the preceding 60 minutes to provide an overall measure of individual responsiveness \[[@CR22]\]. Our validation studies found that this was less subject to the "on-off" fEMG artifacts that can confound the bispectral index and entropy, which are primarily based on EEG data \[[@CR17], [@CR21]\]. RI is intended to provide an objective integrated measure of patient arousal in relation to underlying neurological status, external stimulation, and administered sedation and analgesia over the preceding 60 minutes. RI values are low during deep sedation, but can also be low in other forms of coma and natural sleep, and during periods of minimal external stimulation \[[@CR20]\]. These non-linear relationships with sedation and neurological status were the rationale for using low RI values as a prompt or alert, rather than using specific values as a sedation target. Despite the need to explore the potential reasons for a low RI value during decision-making, the interviewed nurses valued the information. The continuous objective simple presentation using colour in addition to numeric data was considered useful, and data were felt to support decision-making in relation to sedation reduction, but also to justify maintenance of the current sedation state. These qualitative findings further supported the RI concept, especially as many nurses had relatively limited experience using the technology when interviewed.

This was a proof-of-concept study, and a convenience sample size was used rather than a calculated sample size to demonstrate clinically important differences in patient outcomes. Non-significant trends towards quicker extubation, higher RI values and lower sedative drug use were observed in the intervention group, which mainly occurred in the subgroup in whom RI values were \<20 at baseline, in whom there was greatest plausibility for an effect on clinical management. The frequent use (\>80 %) of sedation holds and a protocol that included prompted hourly sedation assessment using the RASS score make it possible that the best practice provided in both groups decreased the effect size attributable to RI monitoring. However, our aim in this proof-of-concept study was to explore the safety and potential effectiveness of RI monitoring as an incremental intervention. These preliminary data are consistent with a potential utility for RI monitoring as an adjunct to regular clinical assessments, even when these are used frequently, but further studies are needed to evaluate the effectiveness of RI monitoring in larger and more varied ICU settings.

We did not observe significant differences in the RASS scores either for the overall cohort, or for the analysis restricted to patients with RI \<20 at the start of monitoring. The relatively small patient numbers, wide variation in RASS scores, categoric nature of RASS data, and low overall proportion of time with RASS \< −4 during the 48-hour intervention period may explain this finding. Our previous validation studies clearly indicate that clinical sedation scales, which score responses to specific stimuli at defined time points, are not directly comparable to the RI, which is a measure of overall arousal during clinical management over the previous 60 minutes of care \[[@CR20], [@CR21]\]. Although the RASS score has good discriminant ability and reliability in published studies \[[@CR23]\], it is potentially subject to recording bias by clinical staff and is semi-subjective. Our proof-of-concept study provides quantitative and qualitative data suggesting that the objective RI data could influence nursing staff despite the frequent (hourly) recording of RASS score. However, further larger studies are needed to determine whether RI monitoring can increase overall RASS scores, and whether this translates into improved sedation quality and clinical outcomes.

Current evidence-based guidelines do not recommend the routine use of technologies to guide sedation management \[[@CR13]\]. Published studies with existing technologies suggest variable discriminant validity, and problems with artefact suppression and confounding of algorithms by fEMG frequencies \[[@CR16], [@CR24], [@CR25]\]. There are few published trials of technology-guided sedation and those published do not demonstrate benefit \[[@CR19]\]. The RI was iteratively developed to address the problems encountered with other technologies, but further trials with power to detect differences in clinically important outcomes are needed to further evaluate its clinical effectiveness and cost-effectiveness.

Strengths of our trial include the prospective measurement of multiple proof-of-concept and safety outcomes, and the inclusion of a nested qualitative study with clinical users. The direct comparison of RI data between the groups with blinding of RI data from clinical staff in the control group reduced the chance of bias for this outcome. Weaknesses include the limited sample size, and the exclusion from analysis of randomised patients in whom subsequent consent could not be obtained. However, for a proof-of-concept trial in which comparisons of patients treated as per protocol was of the greatest interest, we think it unlikely that this was an important source of bias.

Conclusions {#Sec19}
===========

In conclusion, we have shown that the use of RI monitoring as an adjunct to decision-making by bedside nurses has potential utility for improving sedation-management without increasing sedation-related adverse effects. The technology was acceptable and considered potentially useful by ICU nurses.

Key messages {#Sec20}
============

The Responsiveness Index is a novel sedation-monitoring technology that may have clinical utility for modifying nurse decision-making in mechanically ventilated sedated critically ill patientsAltering sedation using Responsiveness-Index-guided decision support did not increase sedation-related adverse eventsNursing staff found Responsiveness Index monitoring a useful adjunct to decision-making, particularly the objective continuous data and simple colour-coded data presentationLarger trials of sedation management using Responsiveness Index monitoring are justified

Additional files {#Sec21}
================

Additional file 1:**Pilot trial protocol for a randomised controlled trial of intensive care management of sedation using patient responsiveness in critical care (IMPROVE).** (PDF 399 kb)Additional file 2:**Summary of qualitative analysis of interviews with ICU nurses regarding their views and opinions of responsiveness index monitoring in the IMPROVE pilot trial.** (PDF 288 kb)

APACHE

:   acute physiology and chronic health evaluation

CRF

:   case record file

EEG

:   electroencephalogram

fEMG

:   facial electromyelogram

ICU

:   Intensive Care Unit

NMBA

:   neuromuscular blocking agents

RASS

:   Richmond agitation-sedation scale

RI

:   Responsiveness Index

SOFA

:   sequential organ failure assessment
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